Status and phase
Conditions
Treatments
About
To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
325 participants in 2 patient groups
Loading...
Central trial contact
Santen Pharmaceutical Co., Ltd Clinical Operations
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal